Lysosomal Acid Lipase Deficiency Leading to Liver Cirrhosis: a Case Report of a Rare Variant Mutation
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
MEXICAN ASSOC HEPATOLOGY
Autores
CUNHA-SILVA, Marlone
CORREA, Barbara R.
LOPES, Tirzah M.
ARRELARO, Raquel C.
FERREIRA, Gabriel L.
I, Marcello Rabello
SEVA-PEREIRA, Tiago
ESCANHOELA, Cecilia A. F.
ALMEIDA, Jazon R. S.
Citação
ANNALS OF HEPATOLOGY, v.18, n.1, p.230-235, 2019
Resumo
Lysosomal acid lipase deficiency is a poorly diagnosed genetic disorder, leading to accumulation of cholesterol esters and triglycerides in the liver, with progression to chronic liver disease, dyslipidemia, and cardiovascular complications. Lack of awareness on diagnosis of this condition may hamper specific treatment, which consists on enzymatic replacement. It may prevent the progression of liver disease and its complications. We describe the case of a 53-year-old Brazilian man who was referred to our center due to the diagnosis of liver cirrhosis of unknown etiology. He was asymptomatic and had normal body mass index. He had dyslipidemia, and family history of myocardial infarction and stroke. Abdominal imaging tests showed liver cirrhosis features and the presence of intrahepatic calcifications. Initial investigation of the etiology of the liver disease was not elucidated, but liver biopsy showed microgoticular steatosis and cholesterol esters deposits in Kuppfer cells. The dosage of serum lysosomal acid lipase was undetectable and we found the presence of a rare homozygous mutation in the gene associated with the lysosomal acid lipase deficiency, (allele c. 386A > G homozygous p. H129R).
Palavras-chave
Cholesterol ester storage disease, Intrahepatic calcifications, Liver steatosis, Sebelipase alfa, Enzyme replacement
Referências
- Agencia Nacional de Vigilancia Sanitaria (Anvisa), 2017, KAN ALF APPR
- Ambler GK, 2013, JIMD REP, V8, P41, DOI 10.1007/8904_2012_155
- [Anonymous], 2016, APPL NUMB 125561 OR
- ARTERBURN JN, 1991, J CLIN GASTROENTEROL, V13, P482, DOI 10.1097/00004836-199108000-00028
- Balwani M, 2013, HEPATOLOGY, V58, P950, DOI 10.1002/hep.26289
- Bay L, 2017, ARCH ARGENT PEDIATR, V115, P287, DOI [10.5546/aap.2017.eng.287, 10.5546/aap.2017.287]
- Bernstein DL, 2013, J HEPATOL, V58, P1230, DOI 10.1016/j.jhep.2013.02.014
- Burton BK, 2015, NEW ENGL J MED, V373, P1010, DOI 10.1056/NEJMoa1501365
- Burton BK, 2015, J PEDIATR GASTR NUTR, V61, P619, DOI 10.1097/MPG.0000000000000935
- Caldwell Stephen, 2010, Curr Gastroenterol Rep, V12, P40, DOI 10.1007/s11894-009-0082-7
- Frampton JE, 2016, AM J CARDIOVASC DRUG, V16, P461, DOI 10.1007/s40256-016-0203-2
- Gramatges MM, 2009, BONE MARROW TRANSPL, V44, P449, DOI 10.1038/bmt.2009.57
- Himes RW, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0214
- KRIVIT W, 1992, BONE MARROW TRANSPL, V10, P97
- LEONE L, 1995, J PEDIATR-US, V127, P509, DOI 10.1016/S0022-3476(95)70103-6
- Maheshwari A, 2006, AM J GASTROENTEROL, V101, P664, DOI 10.1111/j.1572-0241.2006.00478.x
- Paton DM, 2016, DRUG TODAY, V52, P287, DOI 10.1358/dot.2016.52.5.2488974
- Pullinger CR, 2015, J CLIN LIPIDOL, V9, P716, DOI 10.1016/j.jacl.2015.07.008
- Reiner Z, 2014, ATHEROSCLEROSIS, V235, P21, DOI 10.1016/j.atherosclerosis.2014.04.003
- Ries S, 1998, HUM MUTAT, V12, P44, DOI 10.1002/(SICI)1098-1004(1998)12:1<44::AID-HUMU7>3.0.CO;2-O
- Shah D.S., 2015, J CLIN LIPIDOL, V9, P455
- Sreekantam S, 2016, PEDIATR TRANSPLANT, V20, P851, DOI 10.1111/petr.12748
- Su K, 2016, APPL CLIN GENET, V9, P157, DOI 10.2147/TACG.S86760
- Tadiboyina VT, 2005, LIPIDS HLTH DIS, V4, P1
- Tolar J, 2009, BONE MARROW TRANSPL, V43, P21, DOI 10.1038/bmt.2008.273
- Valayannopoulos V, 2017, MOL GENET METAB, V120, P62, DOI 10.1016/j.ymgme.2016.11.002
- Valayannopoulos V, 2014, J HEPATOL, V61, P1135, DOI 10.1016/j.jhep.2014.06.022
- Xu M, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.357707
- Yanir A, 2013, MOL GENET METAB, V109, P224, DOI 10.1016/j.ymgme.2013.03.007